Ultragenyx and Mereo BioPharma: What Analysts Are Saying After Trial Setbacks

Analysts react to disappointing ORBIT and COSMIC trial results for Ultragenyx and Mereo BioPharma, highlighting risks, ratings changes, and what could come next.